Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H21NO |
Molecular Weight | 243.344 |
Optical Activity | ( - ) |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCCC[C@@]13CCN[C@@H]2CC4=CC=C(O)C=C34
InChI
InChIKey=IYNWSQDZXMGGGI-NUEKZKHPSA-N
InChI=1S/C16H21NO/c18-12-5-4-11-9-15-13-3-1-2-6-16(13,7-8-17-15)14(11)10-12/h4-5,10,13,15,17-18H,1-3,6-9H2/t13-,15+,16+/m0/s1
Molecular Formula | C16H21NO |
Molecular Weight | 243.344 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
High-performance liquid chromatography assay for simultaneous determination of dextromethorphan and its main metabolites in urine and in microsomal preparations. | 2001 Apr 15 |
|
Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? | 2001 Nov |
|
A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition. | 2002 Aug 22 |
|
The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. | 2002 Jul 26 |
|
Maintenance of liver functions in rat hepatocytes cultured as spheroids in a rotating wall vessel. | 2003 Jan-Feb |
|
New morphinan derivatives with negligible psychotropic effects attenuate convulsions induced by maximal electroshock in mice. | 2003 Mar 7 |
|
Determination of dextromethorphan and its metabolites in rat serum by liquid-liquid extraction and liquid chromatography with fluorescence detection. | 2003 May 25 |
|
Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism. | 2004 Dec 1 |
|
LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation. | 2004 Dec 25 |
|
Effect of methamphetamine on the pharmacokinetics of dextromethorphan and midazolam in rats. | 2005 Jul-Sep |
|
Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers. | 2005 Jun |
|
3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. | 2005 Mar |
|
Validation of a liquid chromatography-mass spectrometry method to assess the metabolism of dextromethorphan in rat everted gut sacs. | 2005 May 5 |
|
3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro. | 2006 Dec |
|
Selective effects of nitric oxide on the disposition of chlorzoxazone and dextromethorphan in isolated perfused rat livers. | 2006 Jul |
|
Simultaneous analysis of dextromethorphan and its three metabolites in human plasma using an improved HPLC method with fluorometric detection. | 2007 Nov 1 |
|
Neuropsychotoxicity of abused drugs: potential of dextromethorphan and novel neuroprotective analogs of dextromethorphan with improved safety profiles in terms of abuse and neuroprotective effects. | 2008 Jan |
|
Concise synthesis of dimemorfan (DF) starting from 3-hydroxymorphinan (3-HM). | 2008 Jul |
|
Metabolism of dextrorphan by CYP2D6 in different recombinantly expressed systems and its implications for the in vitro assessment of dextromethorphan metabolism. | 2009 Feb |
|
Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. | 2009 Jul |
|
A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study. | 2009 Nov |
|
Neuropsychotoxic and neuroprotective potentials of dextromethorphan and its analogs. | 2011 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:29:27 GMT 2023
by
admin
on
Fri Dec 15 19:29:27 GMT 2023
|
Record UNII |
IL94262N7K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
9634
Created by
admin on Fri Dec 15 19:29:27 GMT 2023 , Edited by admin on Fri Dec 15 19:29:27 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB09375MIG
Created by
admin on Fri Dec 15 19:29:27 GMT 2023 , Edited by admin on Fri Dec 15 19:29:27 GMT 2023
|
PRIMARY | |||
|
100000083600
Created by
admin on Fri Dec 15 19:29:27 GMT 2023 , Edited by admin on Fri Dec 15 19:29:27 GMT 2023
|
PRIMARY | |||
|
873
Created by
admin on Fri Dec 15 19:29:27 GMT 2023 , Edited by admin on Fri Dec 15 19:29:27 GMT 2023
|
PRIMARY | |||
|
NORLEVORPHANOL
Created by
admin on Fri Dec 15 19:29:27 GMT 2023 , Edited by admin on Fri Dec 15 19:29:27 GMT 2023
|
PRIMARY | Norlevorphanol is an opioid analgesic of the morphinan class. It was never marketed. | ||
|
C054116
Created by
admin on Fri Dec 15 19:29:27 GMT 2023 , Edited by admin on Fri Dec 15 19:29:27 GMT 2023
|
PRIMARY | |||
|
216-236-4
Created by
admin on Fri Dec 15 19:29:27 GMT 2023 , Edited by admin on Fri Dec 15 19:29:27 GMT 2023
|
PRIMARY | |||
|
5463854
Created by
admin on Fri Dec 15 19:29:27 GMT 2023 , Edited by admin on Fri Dec 15 19:29:27 GMT 2023
|
PRIMARY | |||
|
1531-12-0
Created by
admin on Fri Dec 15 19:29:27 GMT 2023 , Edited by admin on Fri Dec 15 19:29:27 GMT 2023
|
PRIMARY | |||
|
C170233
Created by
admin on Fri Dec 15 19:29:27 GMT 2023 , Edited by admin on Fri Dec 15 19:29:27 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105152
Created by
admin on Fri Dec 15 19:29:27 GMT 2023 , Edited by admin on Fri Dec 15 19:29:27 GMT 2023
|
PRIMARY | |||
|
m8066
Created by
admin on Fri Dec 15 19:29:27 GMT 2023 , Edited by admin on Fri Dec 15 19:29:27 GMT 2023
|
PRIMARY | Merck Index | ||
|
IL94262N7K
Created by
admin on Fri Dec 15 19:29:27 GMT 2023 , Edited by admin on Fri Dec 15 19:29:27 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |